ADR120S

ADR120S EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ADR120S (3750.T) as of Nov 3, 2026 is -906.18 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -757.31 M JPY — a change of 19.66% (lower).

EBITDA

-906.18 MJPY

YoY

19.66%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ADR120S is 2026 -906.18 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ADR120S was 2025 -757.31 M JPY. It decreases by 19.66% lower compared to the previous year.

The ADR120S EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
330.19 M JPY
Jan 1, 2020
489.03 M JPY
Jan 1, 2021
-507.78 M JPY
Jan 1, 2022
-225.82 M JPY
Jan 1, 2023
-513.98 M JPY
Jan 1, 2024
-564.36 M JPY
Jan 1, 2025
-757.31 M JPY
Jan 1, 2026
-906.18 M JPY
The ADR120S EBITDA history
YEAREBITDAYoY
-906.18 MJPY+19.66%
-757.31 MJPY+34.19%
-564.36 MJPY+9.80%
-513.98 MJPY+127.61%
-225.82 MJPY-55.53%
-507.78 MJPY-203.83%
489.03 MJPY+48.11%
330.19 MJPY+138.79%
138.27 MJPY-134.71%
-398.42 MJPY+63.52%
-243.66 MJPY-159.57%
409.05 MJPY+27.92%
319.76 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ADR120S Stock analysis

What does ADR120S do? ADR120S Inc generates revenue through its Real Asset segment, which involves buying and selling real estate, developing and operating hotels, and investing in real estate projects. The Medical segment focuses on regenerative medicine, selling medical equipment like the Celusion centrifuge and Celusion cell therapy kit, and providing cell therapy services. The company serves clients in real estate development, hotel operations, and healthcare sectors, with products targeting medical facilities and clinics specializing in regenerative treatments. The Real Asset segment handles property transactions, hotel management, and real estate investments, while the Medical segment offers cell therapy solutions through its branded products. Both segments target businesses seeking to expand in real estate or adopt advanced medical technologies, with the Celusion products being key revenue drivers in the healthcare market. ADR120S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADR120S stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ADR120S is -906.18 M JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ADR120S changed from -757.31 M JPY to -906.18 M JPY, representing a 19.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ADR120S since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ADR120S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — ADR120S

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — ADR120S